The Huffington Post [7 July, 2017]
“Warning issued over super strain of untreatable gonorrhoea fuelled by oral sex”
Good Morning Scotland [7 July, 2017]
Interview with Manica Balasegaram, Director of GARDP
NATURE [7 July, 2017]
“Untreatable gonorrhoea on the rise worldwide”
BBC [7 July, 2017]
“Oral sex producing unstoppable bacteria”
MDR Wissen [7 July, 2017]
“Medikamente gegen Gonorrhö wirken bald nicht mehr” – “Drugs against gonorrhea will soon no longer work”
Süddeutsche Zeitung [7 July, 2017]
“WHO warnt vor unbehandelbarer Geschlechtskrankheit” – “WHO warns against sexually transmitted diseases”
Pharmazeutische Zeitung [7 July, 2017]
“WHO: Behandlung der Gonorrhö wird immer problematischer” – “WHO: Treatment of gonorrhea is becoming more problematic”
[Geneva – 7 July 2017]
Joint WHO and GARDP/DNDi News Release: Data from 77 countries show that antibiotic resistance is making gonorrhoea – a common sexually-transmitted infection—much harder, and sometimes impossible, to treat.
[Boston, Geneva – 6 July 2017]
First partnering deal for newly-created GARDP with Entasis includes access and stewardship strategy to tackle drug-resistant gonorrhea
Zoliflodacin, a novel first-in-class oral antibiotic and one of the only treatments in development to address the rapidly-growing threat of drug-resistant gonorrhea will enter pivotal trials, thanks to a new partnership between the not-for-profit Global Antibiotic Research and Development Partnership (GARDP) and Entasis Therapeutics. The announcement comes as the World Health Organization (WHO) releases alarming new data today showing that of 77 countries surveyed across the world, more than 60% report resistance to the last-resort treatment for gonorrhea.
[Deutsch] [Français] [Português]
STAT [6 July, 2017]
“New data show gonorrhea increasingly resistant to antibiotics”
[Geneva, Switzerland – September 22, 2016]
The Drugs for Neglected Diseases initiative (DNDi) is pleased to announce financial support from the Swiss Government to the DNDi-WHO joint initiative Global Antibiotic Research & Development Partnership (GARDP) launched earlier this year.